Loading stock data…
BVS
$10.11+0.24 (+2.43%)
Market ClosedLast close May 1
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Bioventus Inc. in the Healthcare sector is trading at $10.11. The stock is currently near its 52-week high of $10.76, remaining 30.3% above its 200-day moving average. Technical signals show neutral RSI of 59 and bearish MACD signal, explaining why BVS maintains its current momentum and trend strength. The Whystock Score of 85/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Neutral momentum (RSI 59) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$10.11
Potential Downside
85.8%
Whystock Fair Value$1.44
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Bioventus Inc., a medical device company, focuses on relieving pain and addressing musculoskeletal therapies in the United States and internationally. The company's product portfolio includes pain treatments, which comprise various intra-articular an...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$656.77M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
29.42
Beta
Defensive asset. Lower volatility than the S&P 500.
0.69
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-69.06%
Volume
Today's trading volume
349,124
Recent News
Are Investors Undervaluing Amneal Pharmaceuticals (AMRX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Strength Seen in Bioventus (BVS): Can Its 6.6% Jump Turn into More Strength?
Bioventus (BVS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
ASX Penny Stocks To Watch In April 2026
The Australian market is experiencing a surge with the ASX 200 futures showing a significant hike, buoyed by renewed global optimism following geopolitical developments. In such dynamic conditions, investors often look beyond established giants to uncover potential growth opportunities in lesser-known areas. Penny stocks, while an older term, continue to capture interest as they represent smaller or newer companies that can offer substantial growth prospects at lower price points. When these...
Are Investors Undervaluing Bioventus (BVS) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
How The Bravura Solutions (ASX:BVS) Story Is Shifting On Earnings Guidance And Dividend Moves
The fair value price target for Bravura Solutions sits at A$2.684, with no reset to that anchor even as analysts revisit their models. Recent commentary focuses on how this steady A$2.684 valuation compares with updated views on risk and earnings, suggesting a more fine tuned but still balanced stance on upside and execution risk. As you read on, you will see how these price target assumptions are evolving and what to watch next in the Bravura story. Stay updated as the Fair Value for Bravura...